Compare Novavax Inc (NVAX) vs Rivian Automotive, Inc. (RIVN) Price & Performance

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.

Rivian (RIVN) trades at $16.005, down 2.35% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company continues to report significant losses, with a net income margin of -54.95% for 2025, though revenue has grown to $5.39 billion. Recent news highlights the R2 vehicle launch and a partnership with Uber, providing potential growth catalysts amid ongoing cash burn concerns.

The outlook remains speculative; RIVN offers high growth potential through new vehicle ramps and software margins, but substantial execution risks and negative cash flow pose threats to near-term stability. Analyst consensus is cautiously optimistic with a $18.70 price target, yet the stock's path depends heavily on achieving profitability milestones.